{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:34:04Z","timestamp":1785598444399,"version":"3.56.0"},"reference-count":67,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Oligometastatic prostate cancer represents a distinct biological state between localized and widely metastatic disease, characterized by a limited number of lesions. Stereotactic body radiotherapy (SBRT) has emerged as a key metastasis-directed therapy (MDT), enabling precise ablation of metastatic lesions with minimal toxicity. Prospective clinical trials such as SABR-COMET, STOMP, ORIOLE, RADIOSA, and EXTEND have shown that SBRT delays disease progression, prolongs progression-free survival, and postpones the need for systemic therapy, while maintaining a favorable safety profile. Nevertheless, methodological limitations persist, including heterogeneity in defining oligometastatic disease, variability in dosing and fractionation, and the lack of predictive biomarkers. Ongoing phase III trials aim to validate the integration of SBRT with modern systemic therapies, including next-generation androgen receptor pathway inhibitors, to optimize clinical outcomes in hormone-sensitive and castration-resistant oligometastatic prostate cancer. This review summarizes current evidence, clinical applications, and future directions for SBRT in this patient population.<\/jats:p>","DOI":"10.3390\/life16040550","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:33:33Z","timestamp":1774622013000},"page":"550","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1719-622X","authenticated-orcid":false,"given":"Macarena","family":"Teja","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, 28010 Madrid, Spain"},{"name":"Department of Radiation Oncology, GenesisCare-San Francisco de As\u00eds University Hospital, 28002 Madrid, Spain"},{"name":"PhD Program in Medicine and Surgery, Escuela de Doctorado, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-5450","authenticated-orcid":false,"given":"Miguel Angel","family":"Berenguer Frances","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vithas Consuelo Hospital, GenesisCare, 46007 Valencia, Spain"},{"name":"Department of Radiation Oncology, La Fe Hospital, 46206 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"Fernando","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, 28010 Madrid, Spain"},{"name":"Department of Radiation Oncology, Ram\u00f3n y Cajal University Hospital, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-9904","authenticated-orcid":false,"given":"Nicolas","family":"Feltes Ben\u00edtez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Terrassa University Hospital, 08221 Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Stoica","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Torrej\u00f3n University Hospital, 28850 Torrej\u00f3n de Ardoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5779-0880","authenticated-orcid":false,"given":"Andrea","family":"Puertas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare Granada, 18008 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5339-8038","authenticated-orcid":false,"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare, 20141 Milan, Italy"},{"name":"Department of Oncology and Hematology-oncology, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai 400012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-0234","authenticated-orcid":false,"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vithas Consuelo Hospital, GenesisCare, 46007 Valencia, Spain"},{"name":"Department of Radiation Oncology, La Fe Hospital, 46206 Valencia, Spain"},{"name":"Department of Medicine, School of Medicine, Health and Sport, European University of Madrid, 28670 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2006.09.7469","article-title":"Stereotactic body radiation therapy in multiple organ sites","volume":"25","author":"Timmerman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy","volume":"44","author":"Fowler","year":"2005","journal-title":"Acta Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early-stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Joiner, M.C., and van der Kogel, A. (2009). Basic Clinical Radiobiology, Hodder Arnold. [4th ed.].","DOI":"10.1201\/b15450"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicentre phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Five-year results of a randomized phase II trial of surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence","volume":"38","author":"Ost","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation versus stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): A randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study","volume":"43","author":"Kishan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","article-title":"Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial","volume":"88","author":"Sherry","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastatic disease revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13938","article-title":"Prevalence and prognosis of low-volume oligorecurrent hormone-sensitive prostate cancer","volume":"120","author":"Lambert","year":"2017","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Catherine Park ESTRO\u2013ASTRO consensus on oligometastatic disease","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","article-title":"Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): A systematic review and individual patient data meta-analysis from the X-MET collaboration","volume":"27","author":"Tang","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111041","DOI":"10.1016\/j.radonc.2025.111041","article-title":"The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, Phase II RADIANT trial","volume":"210","author":"Ruicci","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-023-02268-3","article-title":"PERSIAN trial (NCT05717660): An ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative \u201ctriplet\u201d for oligometastatic hormone sensitive prostate cancer patients","volume":"41","author":"Francolini","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): A multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Patel, P., Dreibe, S., Attard, G., Cole, A., Diez, P., Frew, J., Guevara, J., Levine, D., McDonald, F., and Mullassery, V. (2025). Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial. Int. J. Radiat. Oncol. Biol. Phys., Advance online publication.","DOI":"10.1016\/j.ijrobp.2025.02.046"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Decaestecker, K., De Meerleer, G., Ameye, F., Fonteyne, V., Lambert, B., Joniau, S., Delrue, L., Billiet, I., Duthoy, W., and Junius, S. (2014). Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): Study protocol for a randomized phase II trial. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-671"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.prro.2024.04.022","article-title":"A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)","volume":"14","author":"Morillo","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109556","DOI":"10.1016\/j.ejrad.2021.109556","article-title":"PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications","volume":"136","author":"Morawitz","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","article-title":"Prospective comparison of whole-body MRI and 68Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"46","author":"Sawicki","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rovera, G., Grimaldi, S., Oderda, M., Marra, G., Calleris, G., Iorio, G.C., Falco, M., Grossi, C., Passera, R., and Campidonico, G. (2024). Comparative Performance of 68Ga-PSMA-11 PET\/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy. Diagnostics, 14.","DOI":"10.3390\/diagnostics14171964"},{"key":"ref_34","first-page":"127","article-title":"Radiolabelled choline versus PSMA PET\/CT in prostate cancer restaging: A meta-analysis","volume":"9","author":"Treglia","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1756287218815793","DOI":"10.1177\/1756287218815793","article-title":"Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET\/CT scans. A systematic review","volume":"11","author":"Moghul","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-Choline PET\/CT in prostate cancer patients with biochemical recurrence: A phase 3, prospective, multicenter, randomized study","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl. Med. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109966","DOI":"10.1016\/j.radonc.2023.109966","article-title":"ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases","volume":"190","author":"Guckenberger","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_38","first-page":"33","article-title":"Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey","volume":"37","author":"Vilotte","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12094-021-02695-6","article-title":"SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis","volume":"24","author":"Cacicedo","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110717","DOI":"10.1016\/j.radonc.2025.110717","article-title":"Stereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines","volume":"205","author":"Nguyen","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.prro.2024.09.011","article-title":"Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines","volume":"15","author":"Franzese","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107284","DOI":"10.1016\/j.lungcan.2023.107284","article-title":"Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines","volume":"182","author":"Mayinger","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"ref_53","unstructured":"(2026, March 14). NCCN Guidelines. Prostate Cancer. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"ref_54","unstructured":"(2026, March 14). EAU Guidelines. Prostate Cancer. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment."},{"key":"ref_55","unstructured":"(2025, November 01). ClinicalTrials.gov: Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients (START-MET) (NCT05209243), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05209243."},{"key":"ref_56","unstructured":"(2025, November 01). ClinicalTrials.gov: Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer (METRO) (NCT04983095), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04983095."},{"key":"ref_57","unstructured":"(2025, November 02). ClinicalTrials.gov: Prostate-Cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients (Oligo-PRESTO) (NCT04115007), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04115007."},{"key":"ref_58","unstructured":"(2025, November 02). ClinicalTrials.gov: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2) (NCT06320067), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06320067."},{"key":"ref_59","unstructured":"(2025, November 02). ClinicalTrials.gov: Local Ablative Therapy for Hormone Sensitive Oligometastatic Prostate Cancer (PLATON) (NCT03784755), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03784755."},{"key":"ref_60","unstructured":"(2026, January 09). ClinicalTrials.gov: MDRT in Prostate Cancer Treated with Long-Term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) (NCT06150417), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06150417."},{"key":"ref_61","unstructured":"(2026, January 09). ClinicalTrials.gov: TERPS Trial for de Novo Oligometastic Prostate Cancer (NCT05223803), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05223803."},{"key":"ref_62","unstructured":"(2025, November 04). ClinicalTrials.gov: Treatment with Darolutamide +\/\u2212 Radiation Therapy for Patients with a Castration Resistant Cancer and Metastases Detected by Functional Imaging (PEACE8) (NCT06276465), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06276465."},{"key":"ref_63","unstructured":"(2025, November 04). ClinicalTrials.gov: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (PILLAR) (NCT03503344), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03503344."},{"key":"ref_64","unstructured":"(2025, November 08). ClinicalTrials.gov: Standard Treatment +\/\u2212 SBRT in Solid Tumors Patients with Between 1 and 3 Bone-Only Metastases (STEREO-OS) (NCT03143322), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03143322."},{"key":"ref_65","unstructured":"(2025, November 08). ClinicalTrials.gov: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4\u201310 Oligometastatic Tumors (SABR-COMET-10) (NCT03721341), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03721341."},{"key":"ref_66","unstructured":"(2025, November 08). ClinicalTrials.gov: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1\u20133 Metastases) Cancer (SABR-COMET-3) (NCT03862911), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03862911."},{"key":"ref_67","unstructured":"(2025, November 08). ClinicalTrials.gov: A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients with up to 10 Oligometastases and a Synchronous Primary Tumor (SABR-SYNC) (NCT05717166), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05717166."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/4\/550\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:44:57Z","timestamp":1774622697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/4\/550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["life16040550"],"URL":"https:\/\/doi.org\/10.3390\/life16040550","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}